Biotech firms partner with contract development and manufacturing organizations (CDMOs) to leverage their expertise in process development, optimization, and scale-up. In this article, we share an exclusive sneak-peek into a recent survey, which explores the main reasons why biotech companies collaborate with CDMOs at different stages of drug development.
To make a new drug candidate market-ready, drug developers need to have the right expertise to develop a robust production process and optimize their drug scale-up, while navigating complex regulatory frameworks.
Large pharma companies may have capabilities in-house for certain aspects of drug development and manufacturing by virtue of their previous experience. Such firms would seek external expertise for specific steps that their internal capabilities may not support.
Small and emerging biotechs with resource and time constraints, on the other hand, often partner with CDMOs right through the drug development and production journey.
The external expertise sought can vary depending on the product type or the phase – from preclinical and clinical to commercial – that a firm is at with its drug.
The post Top Reasons to Outsource Your Early Clinical Pipeline to a CDMO appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
Published on Tue, 19 Oct 2021 08:00:29 +0000 and brought to you by power automate replace text in collection